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Abstract 
Purpose: To formulate and characterize once daily controlled release tablet of loxoprofen sodium.  
Methods: Eudragit RS-100, hydroxylpropyl methylcellulose (HPMC) and pectin were used as release 
retarding polymers. All the formulations were prepared by direct compression method. Various pre-
compression studies were carried out to determine Hausner’s ratio, Carr’s index, angle of repose, bulk 
density and tapped density Differential scanning calorimetry (DSC) studies  and also post-compression 
studies to evaluate hardness, friability, weight variation, drug content, in-vitro drug release were 
conducted on the tablets. The drug release data were subjected to kinetic models, including zero order, 
first order, Hixon Crowell, Higuchi and Korsmeyer-Peppas. 
Results: Compressibility index (7.6 ± 1.32 - 12.5 ± 1.43%), Hausner’s ratio (1.08 ± 0.04 - 1.14 ± 0.03), 
angle of repose (27.78 ± 0.47 - 30.49 ± 0.46°), hardness (6.25 ± 0.27 - 7.21±0.21 kg/cm2), friability 
(0.14 ± 0.06 - 0.28 ± 0.0 %), weight variation (249.5 ± 2.09 - 251.35 ± 2.41 mg) and drug content (97.30 
± 0.28 - 103.70 ± 0.31 %) were within generally accepted limits for the pre-and post-compression 
formulations, respectively. The tablets having the maximum amount of among the three polymers tested 
as matrix materials, HPMC, represented by F3 tablets, exerted better sustained release properties after 
12 h. Release pattern was more of Fickian diffusion followed by Higuchi mechanism.  
Conclusion: The release of the loxoprofen sodium was optimized up to 12 h. 
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The oral route is the most convenient route for 
delivering drugs to systemic circulation. The 
reasons for preferable use of this route are ease 
of administration, patient acceptance and 
flexibility in formulation. Among various oral 
systems, sustained release delivery systems are 
designed to release the drug over an extended 
period of time for maintaining therapeutic drug 
concentration in the blood. Sustained release 
dosage forms have different advantages like 
reduction in dose size, frequency, toxic effects; 
cost of therapy and enhanced patient compliance 
[1].  
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Loxoprofen sodium belongs to the class of non-
steroidal anti-inflammatory drugs (NSAIDs). It is 
a pro-drug that is converted into its metabolite 
after metabolism. Therapeutic activity depends 
upon its metabolites in systemic circulation. The 
drug has less gastric irritation and toxicity as 
compared to other NSAIDs because it is 
absorbed as free acid. It is a drug of choice in 
acute pain and rheumatoid etiologies. Daily 
recommended dose of loxoprofen sodium is 2 to 
3 tablets [2,3]. 
 
Pectin, hydroxypropyl methylcellulose (HPMC) 
and Eudragit RS-100 are examples of polymers 
used in the preparation of sustained release 
formulations due to their release-controlling, 
‘burst’ effect and release retarding properties 
respectively. These are biodegradable, 
biocompatible, easily available polymers that are 
safe for environment [4,5].  
 
The objective of the present work was to 
formulate and evaluate matrix tablets of 
loxoprofen sodium using some polymers in 






Loxoprofen sodium was received as a generous 
gift from Hilton Pharmaceuticals, Karachi, 
Pakistan. Eudragit RS-100, HPMC and Pectin 
polymers were obtained from Neutro 
Pharmaceuticals, Islamabad, Pakistan. Poly vinyl 
pyrollidone (PVP), Micro-crystalline cellulose 
(MCC), avecil, sodium hydroxide (NaOH) and 
Potassium dihydrogen phosphate were 
purchased from E-Merck Germany. All chemicals 
used were of analytical grade. 
 
Computation of sustained release dose 
component 
 
Total dose (Dt) of the drug for sustained release 
can be calculated with the help of prompt dose, 
Dn, and the sustaining dose Ds, i.e., 
 
Dt = Dn + Ds ……………….. (1) 
 
When sustained dose (Ds) at time (t) is equal to 
Dn, Kt the total dose will be low dose is 30 mg 
 
 
Dt = Dn + DnKt …………… (2) 
 
Dt = Dn (1 + DnKt) ……….. (3) 
 
Dt = Dn (1+Kt) …………….. (4) 
 
Dt = Dn (1 + 0.693 × Td/t1/2) ………….. (5) 
 
For loxoprofen sodium, assuming half-life 2 h 
and Dn is 30 mg. Therefore for 12 hours, the 
sustained release (Td), the total dose of drug (Dt) 
will be 154.74 mg (quantity used was 150 
mg/tablet).  
 
Preparation of tablets  
 
Drug and excipients were weighed accurately 
and individually on electronic weighing balance 
(Shimadzu, Japan). All ingredients shown in 
Table 1 were triturated using pestle and mortar 
for particle size reduction with subsequent mixing 
in polythene bags for 10 - 15 min. The powder 
blend was sieved through sieve # 60 having 
diameter of 250 µm to bring uniformity of 
contents. Powder blend was compressed into 
matrix tablets using single punch rotary machine 
(AR-400 Erweka, Germany) [6]. 
 
    Table 1: Composition of Loxoprofen Sodium matrix tablets 
 









F1 60 10 - - 22 
F2 60 20 - - 12 
F3 60 30 - - 2 
F4 60 - 10 - 22 
F5 60 - 20 - 12 
F6 60 - 30 - 2 
F7 60 - - 10 22 
F8 60 - - 20 12 
F9 60 - - 30 2 
     PVP (6 %), Avicel (1 %) and Mg-Sterate (1 %) were used in each formulation 
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Angle of repose 
 
Power blend of each formulation was evaluated 
for angle of repose by funnel technique using Eq 
6 [7]. 
 
Tan ø = h/r ………………………………. (6) 
 
where Ɵ = angle of repose, h = height of blend 
cone, r = radius of base of cone  
 





Powder mixture was poured in graduated volume 
measuring cylinder and bulk volume (Vb) was 
visually noted. After this powder mass (M) was 
measured on electronic weighing balance. Bulk 
density (ρb) was calculated by using equation 7 
[7]: 
 




Measuring cylinder containing known mass (M) 
of powder contents was tapped for specified 
number of tapings. Tapped volume (Vt) was 
noted. Tapped density was calculated by using 
equation 8 [7]: 
 
Tapped density (ρt) = M/Vt ……………. (8) 
  
Carr’s compressibility index 
 
Free flowing property of powder was confirmed 
from compressibility index (I). It was calculated 
by using formula 9 [8]: 
 
Compressibility index (I) = [(Vt – Vb)/Vb] × 100 ….. (9) 
  
Where Vb and Vt are bulk and tapped volume 
respectively.  Carr’s index between 13 -19 % 
confirms good flow and if it is more than 21 % it 




It is another parameter for powder flow 
determination. It is a ratio between two densities 
i.e. tapped (ρt) and bulk (ρb) densities. It uses 
equation 10 for its presentation: 
 
Hausner ratio = ρt/ρb ………………… (10) 
 
Value less than 1.25 is an indicator of good flow 





Twenty tablets were chosen from each 
formulation and weighed on electronic weighing 
balance (Shimadzu, AUW220D Japan). Mean 
weight was calculated and range was 
established by adding and subtracting ± 5 mg in 
average weight according to pharmacopoeial 
limits [9]. The friability of tablets was determined 
using a Roche friabilator (Pharma Test, 
Germany). The friabilator was operated at 25 
rpm for 4 min. Hardness, thickness and 
diameters were calculated by digital hardness 
tester (Pharma Test Germany).   
 
Drug content uniformity assessment 
 
Twenty tablets from each formulation were taken 
and crushed into powder in pestle and mortar. 
Amount of the powder equivalent to 60 mg was 
taken and poured into methanol-water mixture 
(40:60) for extraction purpose. The extract was 
diluted up to 900 ml in 1000 ml volumetric flask 
with extraction mixture of methanol and water 
(this was the first dilution). The sample was 
taken, diluted and filtered. Absorbance of the 
filtered sample was measured at 220 nm using 
UV-Visible spectrophotometer (Pharma Spec 
1700 Shimadzu Japan). Absorbance of pure drug 
was also calculated as done for reference, and 
drug release was calculated as shown in Eq 11 
[10]. 
Drug release (%) = (As/Af) x 100 ………….. (11) 
 
where As and Af are the absorbance of the 
sample and reference, respectively. 
 
In-vitro drug release studies and kinetic 
modeling 
 
USP apparatus –II (Watson Marlo, Stockholm, 
Sweden), Paddle method was used for 
dissolution studies. Phosphate buffer of pH 6.8 
was used as dissolution medium. All release 
studies were performed at ambient conditions i.e. 
37 ± 2 °C. The speed of the apparatus was kept 
50 rpm. Aliquot of 5 ml of the sample was taken 
at regular and predetermined time intervals and 
was replaced by fresh phosphate buffer media. 
Samples were filtered and diluted and their 
absorbance was noted by using UV- Visible 
spectrophotometer at 220 nm [3]. 
 
Different kinetic models were applied to evaluate 
the different release pattern of the drug from the 
matrix tablets. Zero order kinetics (Qt = kot), first 
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order kinetics (log Qt = log Qo – k1t), Higuchi 
model (Qt = kHt1/2) Hixon-Crowell cube root 
model (Qo1/3 – Q11/3 = kCHt) and Korsmeyer-
Peppas model (Mt/M∞ = kKFtn) were applied to the 
data. These models were utilized for the 





The DSC studies were conducted on (SDT, 
Q600 TA USA) mixture of drug and the different 
polymers were heated in sealed Aluminum pan 
at a flow rate of 10 °C/min from 0 to 300 °C. 
Nitrogen flow was kept at 40 ml/min. Sample (4 – 
8 mg) was kept in Aluminum pan. Samples were 





The similarity and difference factor of dissolution 
profiles of reference and sample was determined 
by model independent method (Eq 3). 
 
 ….. (3) 
 
where f2 is the similarity factor, Rt is amount of 
reference drug at different time interval and Tt 





Drug release data was subjected to statistical 
analysis using one-way ANOVA (Dunnet test) at 
95 % confidence interval with the aid of Graph 






The results of the pre-compression studies are 
presented in Table 2, and were within generally 




Results of the DSC studies for the various 
powder blends are presented in Figure 1. 
 
 
Table 2: Pre-compression results for powder blend (mean ± SD, n = 5) 
 









Angle of repose 










0.35 ± 0.01 
0.36 ± 0.02 
0.36 ± 0.01 
0.34 ± 0.00 
0.37 ± 0.00 
0.35 ± 0.01 
0.33 ± 0.02 
0.34 ± 0.02 
0.36 ± 0.01 
0.40 ± 0.02 
0.41 ± 0.01 
0.39 ± 0.00 
0.39 ± 0.01 
0.41 ± 0.01 
0.39 ± 0.00 
0.37 ± 0.01 
0.38 ± 0.01 
0.40 ± 0.02 
12.5 ± 1.43 
12.1 ± 1.37 
07.6 ± 1.32 
12.8 ± 1.38 
09.8 ± 1.47 
10.2 ± 1.41 
10.8 ± 1.48 
10.5 ± 1.33 
10.0 ± 1.54 
1.14 ± 0.01 
1.13 ± 0.02 
1.08 ± 0.04 
1.14 ± 0.03 
1.10 ± 0.01 
1.11 ± 0.04 
1.12 ± 0.02 
1.11 ± 0.03 
1.11 ± 0.03 
29.61 ± 0.51 
28.42 ± 0.44 
28.62 ± 0.48 
29.59 ± 0.52 
30.12 ± 0.49 
27.91 ± 0.53 
27.78 ± 0.47 
28.47 ± 0.54 




Figure 1: DSC thermograms of powder blend 
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The tablet properties of the formulations, shown 
in Table 3, are within the acceptance criteria of 
British Pharmacopoeia. 
 
In-vitro drug release and kinetics 
 
Figure 1 described the percentage drug release 
from the compressed tablets of loxoprofen 
sodium. It was observed that formulations F1, F4 
and F7 showed more than 91 % drug release in 
12 h due to lesser concentrations of the polymers 
i.e., HPMC, Eudragit and pectin, respectively. In 
the case of model dependent approaches all 
formulations followed zero order and Higuchi 
model. Results of zero, first, Higuchi, Hixson-
Crowell are shown in Table 4. F3 formulation had 
maximum concentration of HPMC was selected 
as an optimized formulation due to its pre and 
post compressional results. Similarly, F6 among 
the Eudragit containing formulations were 
compared with formulations F4 and F5 and found 
more similar with F5. In case of pectin containing 
formulations, F9 was the best formulation and 
showed more similar results with F8. 
 
F3 released 89 % drug during 12 hr dissolution 
studies and compared with other formulations 
considering as reference formulation. Difference 
factor (f1) was found to be less than 10 and 
similarity factor (f2) was more than 60 % for F5, 
F6, F8 and F9. F8 was most similar of all these 




Figure 2: Drug release from matrix tablets of 
loxoprofen sodium prepared with HPMC (F1 to F3), 




All the pre-compression studies i.e. angle of 
repose, bulk density, tapped density, Carr’s index 
and Hausner’s ratio all were within the 
pharmacopoeial limits indicating degree of 
fineness and free flowing characteristics of the 
powder blend. Bulk density was observed from 
0.34 to 0.37 g/dl, tapped density of all the 
formulations was between 0.37 to 0.41 gm/dl, 
compressibility index was less than 20 and 
considered excellent for flow properties. 
 
Table 3: Post-compression characteristics of loxoprofen sodium matrix tablets (mean ± SD) 
 









F1 4.01 ± 0.013 6.53 ± 0.23 0.17 ± 0.06 250.95 ± 1.21 98.8 ± 0.15 
F2 4.02 ± 0.010 6.68 ± 0.26 0.21 ± 0.07 251.05 ± 2.14 99.9 ± 0.22 
F3 4.01 ± 0.014 7.21 ± 0.21 0.14 ± 0.06 250.85 ± 1.54 101.07 ± 0.19 
F4 4.01 ± 0.013 6.47 ± 0.28 0.27 ± 0.05 250.45 ± 2.17 103.7 ± 0.31 
F5 4.02 ± 0.011 6.62 ± 0.19 0.19 ± 0.08 250.85 ± 2.32 100.9 ± 0.26 
F6 4.03 ± 0.012 5.19 ± 0.17 0.18 ± 0.09 249.5 ± 2.09 99.7 ± 0.32 
F7 4.02 ± 0.010 6.25 ± 0.27 0.26 ± 0.08 251.35 ± 2.41 97.3 ± 0.28 
F8 4.03 ± 0.012 6.65 ± 0.21 0.28 ± 0.07 250.75 ± 2.15 103.1 ± 0.16 
F9 4.01 ± 0.011 6.98 ± 0.15 0.18 ± 0.06 250.05 ± 1.99 101.3 ± 0.36 
 
Table 4: Kinetics data (correlation coefficient, R2) for matrix tablets of loxoprofen sodium 
 
Formulation Zero order  First order Hixon Crowell  Higuchi  
F1 0.9083 0.7840 0.8751 0.9925 
F2 0.9491 0.8943 0.9134 0.9884 
F3 0.9684 0.9671 0.8895 0.9781 
F4 0.9124 0.9214 0.9493 0.9950 
F5 0.9630 0.9494 0.9431 0.9864 
F6 0.9632 0.9423 0.8863 0.9639 
F7 0.9675 0.8191 0.9534 0.9724 
F8 0.9585 0.9069 0.9083 0.9665 
F9 0.9553 0.9478 0.9419 0.9609 
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Angle of repose was more than 25 and also 
showed excellent characteristics. No drug-
polymer interaction was detected by DSC 
studies. In case of loxoprofen sodium, initially flat 
curve was obtained but when it came into melting 
range, sharp exothermic peak was observed that 
showed its presence as shown in (Figure 1). 
Similarly, in case of HPMC, pectin and eudragit 
RS-100 DSC studies were done alone and in 
combination with drug. All thermograms have not 
exhibited any change when drug were tested 
alone or in combination with polymers as there 
was no shift of peaks with temperature. 
 
In case of post compressional studies the 
hardness (Kg/cm2) of the prepared matrix tablets 
were within the range of 5 to 7 kg. F3 showed 
maximum hardness value due to the minimum 
concentration of microcrystalline sodium. 
Acceptable limits of hardness of all the 
formulations indicated stability of tablets during 
storage, transport and handling. Friability of all 
the formulations (F1-F9) was less than one 
percent; less value of F3 was observed which 
may be due to the crystalline nature of the 
HPMC. Percentage content uniformity of all 
formulations was within the range of 98 to 103 %.  
Phosphate buffer of pH 6.8 were selected for 
dissolution studies for 12 h. All three polymers 
showed good retardation of the drug up-to 12 h. 
Due to presence of carboxylic acid group in 
HPMC maximum controlled was observed at its 
higher concentration which may be due to 
complex formulation of the HPMC molecules. 
Swelling nature of HPMC at higher pH also 
favors the sustained release behavior of F3 
formulations [14]. Decrease in the release of the 
drug was greatly associated with the 
concentration of the polymers because increase 
in the concentrations of the polymers increases 
the carboxylic acid concentration that may be 
made more complex mass and decreased the 
release of the drug. Less polymeric content allow 
greater penetration of fluid which results in 
greater release of the drug [15]. Initially, there 
was less hydration of the polymer that can cause 
greater initial release but when the polymer gets 
hydrated it swells and restricts the drug release 
[16].  
 
Dissolution results were compared with model 
dependent approaches and it was observed that 
values of correlations for zero order were in the 
range of 0.9083 to 0.9675, for first order 
correlations values were in between 0.7840 to 
0.9494. Results revealed that zero order was the 
best description of Loxoprofen tablets which 
have time dependent properties. In case of 
Higuchi model r2 values were in range of 0.9639 
to 0.9925 which was may be due to diffusion 
based release of the loxoprofen sodium from the 
compressed formulations. Previous studies have 
shown that formulations prepared with different 
concentration of HPMC, eudragit RS100 and 
pectin followed the Higuchi model and drug 
release pattern was diffusion controlled [17,18]. 
HPMC was also used by Hanif et al in 
formulating the intermediate release tablets of 
Nimesulide 100 mg and found Higuchi 
dependent release [19]. Similar observations 
were made in the current studies. When the data 
was analyzed by Korsmeyer Peppas model, it 
was observed that as the value of n < 0.49 in 
formulations F1 – F8 they followed Fick’s 
diffusion (case-1 transport) mechanism and F9 
followed non-Fickian diffusion pattern because 
the n > 0.49 [20] but overall drug release was 
governed by diffusion process. F8 was more 
comparable with reference formulation with f1 
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